Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2601-2605

  Shimokata, Tomoya ^a   Ando, Yuichi ^b   Yasuda, Yoshinari ^a   Hamada, Akinobu ^c   Kawada, Kenji ^b   Saito, Hideyuki ^c   Matsuo, Seiichi ^a   Kondo, Masashi ^a   Imaizumi, Kazuyoshi ^a   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; GEMCITABINE; INULIN; PACLITAXEL;

ADULT; AGED; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; CALVER FORMULA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DOSE CALCULATION; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INULIN CLEARANCE; JAPANESE; LUNG TUMOR; MALE; MONOTHERAPY; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 78449277986     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01729.x     Document Type: Article

References (23)

1. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8.
2. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 1984; 44: 1693-7.
3. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
4. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009; 27: 3540-6.
5. Belani CP, Kearns CM, Zuhowski EG et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 676-84.
6. Apple FS, Benson P, Abraham PA, Rosano TG, Halstenson CE. Assessment of renal function by inulin clearance: comparison with creatinine clearance as determined by enzymatic methods. Clin Chem 1989; 35: 312-14.
7. Ando Y, Minami H, Saka H et al. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule. Jpn J Cancer Res 1997; 88: 517-21.
8. Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 1997; 76: 1067-71.
9. Ando M, Minami H, Ando Y et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000; 6: 4733-8.
10. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-70.
11. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54.
12. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-92.
13. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009; 15: 4806-14.
14. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003; 14: 449-54.
15. Stevens LA, Coresh J, Greene T, Levey AS. Assesing kidney function. N Engl J Med 2006; 354: 2473-83.
16. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21: 163-7.
17. Imai E, Horio M, Nitta K et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
20. Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 1997; 76: 502-10.
21. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun 2004; 25: 759-69.
22. Van Der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242-61.
23. Newell DR, Pearson ADJ, Balmanno K et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993; 11: 2314-23.